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Abstract
We argue that reluctance to invest in drug treatments to fight the AIDS
epidemics in developing countries is largely motivated by severe losses occur-
ring from the future albeit uncertain appearance of a curative vaccine. We
design a set of securities generating full insurance coverage against such losses,
while achieving full risk-sharing with vaccine development agencies. In a gen-
eral equilibrium framework, we show that those securities are demanded to
improve social welfare in developing countries, to increase current investment
in treatments and the provision of public goods. Even though designed for
AIDS, those securities can also be applied to other epidemics such as Malaria
and Tuberculosis.
Keywords: HIV/Aids funding, security design, therapeutic innovation,
health underinvestment, HIV/Aids vaccine.
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1 Introduction
The scale of the HIV/AIDS epidemics has exceeded the most pessimistic forecasts:
some 42 million people worldwide are currently estimated to be HIV-infected and
95% of these live in developing countries. Five to six million of those living with
HIV/AIDS are probably in need of antiretroviral (ARV) drugs (UNAIDS 2003).
To tackle this crisis, the international community has increased funding in order to
subsidize access to ARV drugs (Moatti et al. 2003) in developing countries, since this
life-long ARV drugs treatment has proven to be highly efficient in drastically reducing
morbidity and mortality associated with HIV infection. Specifically, those funds aim
to foster prevention, staff training, building capacities and local drugs production in
developing countries. One of the motivations of this campaign is that, beyond the
medical emergency, fighting AIDS is also a critical part of reducing the poverty gap
worldwide as argued by Sachs (2004).
A total of US$ 8.3 billion have been estimated to be available in 2005 from a
range of different financial sources including the G7, the European Commission and
the Global Fund, and about US$ 8.9 billion and US$ 10 billion in 2006 and 2007
respectively. Additionally, an estimated US$ 2.6 billion for 2005, US$ 2.8 billion for
2006 and US$ 3 billion for 2007 are to be provided by domestic spending (public and
out-of-pocket expenditures by affected individuals and families) in the 135 middle
and low-income countries. This amount is not expected to significantly increase.
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Nevertheless, governments’ investments in developing countries do not match the
magnitude of the problem, since “... some countries are in a position to contribute
more government resources to [fight] AIDS” (UNAIDS (2005), p. 11). For instance,
the estimated number of people receiving ARV therapy in developing countries cur-
rently ranges between 630 000 and 780 000, which corresponds to a 12 % coverage
rate of estimated patients in need of treatment (WHO 2004). Current investments in
ARV therapy are nonetheless critical to control the propagation of the epidemics and
its economic externalities, on top of reducing current mortality (Moatti et al. 2004).
The main explanation advanced so far to this reluctance to invest is that ARV
costs are prohibitive and represent a major crowding out of public resources (Harling
et al. 2005). For instance, AIDS-related expenditures amounted to already 0.842%
of the total expenditures of South Africa in 2004 (Blecher and Thomas 2005).
Our contribution regarding this reluctance to invest in drugs treatments is two-
fold. We first argue that the future albeit uncertain appearance of a therapeutic
vaccine, more effective both medically and economically, is a major disincentive to
current investment. The intuition is that this innovative treatment technology will
trigger severe losses in terms of sunk costs and upgrading costs when introduced, as
detailed later. Reluctance to invest is thus a rational economic consequence with a
direct impact on the death toll and the evolution of the epidemics (Dixit and Pindyck
(1994), Chapters 5-9). Second, we design a set of financial securities generating full
insurance coverage against such losses for developing countries, while achieving full
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risk-sharing with bodies in charge of developing the vaccine. We show that those
securities are demanded to increase social welfare in developing countries, current
investments in treatments and R&D funds in innovative treatment technologies.
In the specific case of AIDS, the most promising and innovative technology is a
therapeutic vaccine, capable of both treating infected patients and reducing HIV-
transmissibility by diminishing the mean viral load in the population. The vaccine
could therefore delay the need for ARV drugs for several years (see Wei et al. (2004)
and ANRS (2004) for the latest developments in HIV vaccine research). Such effects
can be achieved with one injection only, and the production cost is small.
Developed countries, mostly the U.S. and France with public funds up to 90%
(Kremer and Glennerster 2004), are developing such a therapeutic vaccine to be
delivered at no cost (or at production cost) to developing countries. Current estimates
of worldwide spending in HIV vaccine research range between US$ 600-650 million,
as detailed in Kremer and Glennester (2004) and IAVI (2004).
The remainder of the paper is organized as follows. In Section 2, we describe
the losses generated by the vaccine appearance, in Section 3 we design the securities
allowing full insurance coverage against such losses and achieving full risk-sharing with
vaccine development agencies, in Section 4 we carry out a welfare analysis showing
that our securities are demanded to increase social welfare and current investments
in drugs therapy, in Section 5 we detail the policy implications for AIDS financing
campaigns and other epidemics, and the Appendix contains all the technical proofs.
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2 Economic impact of the vaccine
We now study the economic consequences of a vaccine appearance. The problematic
aspect of ART provision, and more generally of health investments, is that switching
from technology to another is particularly costly (Palmer and Smith 2000). This is
true for investments in developing countries, and also for bodies currently producing
the drugs. Nevertheless, actual costs in the case of AIDS are typically difficult to
accurately estimate, mostly because of lack of reliable data and field studies. We rely
on available aggregate data from international agencies such as the United Nations
to document this problem.
The most natural consequence of a vaccine appearance is that sunk costs in ARV
investments will be lost. Often forgotten albeit important sunk costs are managerial
costs (also called program level costs) arising at administrative levels outside the point
of health care delivery. Such costs include services such as management of AIDS
Programs, monitoring and evaluation, staff training, supervision of personnel and
patient tracking. Managerial costs are particularly stringent because most decisions
remain at government level, instead of a centralized body coordinating actions (Gupta
et al. 2004). United Nations estimations assert that such costs amount to US$ 1.236
billion in 2006, US$ 1.095 billion in 2007 and US$ 1.281 billion for all 135 low and
middle income countries (UNAIDS 2005). In South Africa for instance, program level
costs are estimated to be 8% of the global investment in ARV treatment program
over the same period (Cleary et al. 2005).
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Other managerial aspects might also trigger sunk costs when a vaccine becomes
available. For instance, short-run inefficiencies are likely to occur when resources
such as HIV-dedicated hospitals and services are re-oriented to other activities. This
reorientation will critically depend on managerial supervision, and the magnitude of
the inefficiency may turn out to be severe in countries where the public sector has
very limited managerial capacity (Dixit 2003).
Other severe losses are on the drugs production side. Even if drug plants can par-
tially be redirected to the production of other drugs such as antibiotics, the nature
of ARV treatment will make any reshuffling of the whole production process par-
ticularly costly. Indeed, the pharmaceutical industry traditionally suffers from rigid
manufacturing with strongly specialized production equipment, together with costly
regulatory requirements (Shah 2004). In case of reshuffling of a production chain,
regulatory requirements will impose for instance that all expensive quality control
tests will have to be renewed (Blau et al. 2000). Another costly aspect of drugs
manufacturing is the extensive use and processing of intermediary goods (primary
active ingredients), with lengthy periods to obtain some of those goods and specific
processing technologies. Switching from one production to another will necessarily
require to change most stages of the production chains, with new equipment needed
at every level (Shah 2004). An accurate evaluation of those reshuffling costs requires
case-by-case field studies to estimate them; however, there is a growing literature in
Engineering emphasizing that such costs should be significant (Shah 2005).
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Another consequence of a vaccine appearance is that resources from international
agencies, subsidizing governments to foster treatments (up to 76% of the overall
budget worldwide in 2005; UNAIDS (2005)) will no longer be available to developing
countries. A significant amount of international subsidies will be reallocated to the
vaccine production, more effective both economically and medically, leading in turn
to a decrease in subsidies to developing countries. This issue is critical since health
infrastructures in developing countries, built and operated mostly with international
subsidies, will then have to be operated with national funds. Whether it remains cost-
effective to operate all HIV-dedicated hospitals and services and to reshuffle all drugs
factories cannot be established from aggregate data, although when doing so one must
consider the crowding-out effect of such costs in situations of limited resources and
no international subsidies.
Investments in health infrastructures are made to fight a major national crisis such
as AIDS. With this crisis about to end, as it would conceptually be the case with
a therapeutic vaccine, reallocation of all such investments to other health issues will
likely lead to significant overspending in less critical national priorities. Independently
of the positive externalities in health services, developing countries also need resources
to face many other critical challenges such as water supply and famine.
When anticipated, the above losses explain current under-investment in compari-
son to a situation where opportunities to hedge against the risk of a vaccine appear-
ance exist. The next section is devoted to designing such insurance opportunities.
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3 Designing the securities
The question that we now address is what financial tools can be designed to foster
current investments in ARV treatments, allowing to hedge against the future albeit
uncertain availability of this innovative treatment technology.
A standard insurance contract, allowing a particular government to cover produc-
tion losses associated with a successful vaccine, is ineffective in practice. Indeed, the
main shortcoming of such a contract is that it would transfer the risk to the issuer,
who would be unable to diversify a large part of the transaction. Given current regu-
latory practices, the value at risk associated with such a contract would typically be
too high to be allowed.
We next describe a set of financial securities tackling all of the above problems.
Those securities take the form of derivatives with payment contingent on the appear-
ance (or not) of a successful vaccine to be issued both by insurance companies and
international agencies, with the idea of “securityzing” a broad insurance contract.
Our construction is reminiscent of Shiller’s proposition to create macro securities
(Shiller 2003). While Shiller designs his construction as a way of hedging risks at an
individual level, we consider a mechanism that is at an institutional level. A financial
tool allowing governments to hedge against vaccine appearance can be constructed as
follows. Consider a financial asset available at the time decisions to produce ARV are
made, with a fixed maturity date and small payoff if a successful vaccine is released
before the maturity date. Somewhat similar types of derivatives are weather deriva-
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tives, with the common idea that the security has no underlying real asset. We call
this derivative an Arrow security. The welfare analysis developed in the next section
shows that Arrow securities are demanded by developing countries to increase social
welfare as well as current investments in ARV treatment. Such securities will also
naturally be demanded by pharmaceutical companies producing drugs. There are two
reasons for this demand. First, ARV drugs are still patented in developed countries,
whereas following the Doha Declaration in 2003 WTO regulations offer possibilities
for developing countries affected by AIDS to overcome existing intellectual property
rights through compulsory licensing. Second, marketing a therapeutic vaccine would
render de facto current drugs patents virtually obsolete.
Since full risk-transfer is impossible with the above security alone, profit-seeking
organizations are naturally unwilling to market such securities. This problem can
be solved by introducing the complementary asset of the Arrow security. Consider
a financial asset identical to an Arrow security, with the difference that the same
payment is made if a vaccine is not approved for distribution by an independent
testing agency before maturity date; further conditions on payment delivery must
be added to remove a natural moral hazard, as detailed later. This complementary
asset is demanded by public agencies responsible for developing the vaccine, since
failure can henceforth be financially compensated leading to additional funds for
further research. This security can also induce typically reluctant private companies
to engage in vaccine R&D (Kremer and Snyder 2004; Geoffard and Philipson 1997).
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A natural moral hazard is that vaccine companies, even public, purchase this com-
plementary security without making necessary investment to obtain a vaccine. There
are two main aspects to this moral hazard. The first aspect is that a vaccine com-
pany may start the testing trial with a product where small (if any) R&D investment
has been made. The second aspect is that such a company may not pay for further
testing and thus generate profits by exercising the complementary security. This last
aspect is important since, in practice, the trial is paid for by the pharmaceutical
company for a total that amounts to one-third of the development budget (Klausner
et al. (2003)). Those issues can be removed by making payment contingent on some
standard decisions by health control agencies (such as for instance the F.D.A. in the
U.S.) to approve distribution, as follows.
The first aspect above can be removed by making payment conditional on approval
by the testing agency to start the trial for at least one vaccine, based on enough
scientific evidence that the candidate vaccine can be successful. ELISPOT assays,
as described in IAVI (2004), are reliable pre-tests for this purpose. Failure to get
this approval prevents payment, and thus significant investment in R&D to obtain a
testable product becomes necessary to exercise the complementary security.
The second aspect can be solved by requiring that payment be also conditional
on the approval from the testing agency to stop all the trials before their end, instead
of unilateral withdrawals from vaccine agencies. With this last condition, vaccine
agencies cannot avoid testing costs if they want to exercise the security.
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Another critical aspect for implementation is the estimation of the risk; i.e., in
our case the estimation of the probability of appearance of a successful vaccine. The
scientific and technical procedure to fulfill in order to certify the effectiveness of a
new product are well defined with a high level of quality control, and allows for such
an estimation. For instance, mandatory progress reports during the testing trial, as
described in Klausner et al. (2003) for AIDS vaccines and routinely done for all other
tested drugs, allows to compute the conditional success probability of the vaccine over
time, when compared to the performances of similar products during their trials.
The combination of the Arrow security and its complementary naturally allows
for complete risk-transfer, and thus these securities are issuable in the same way
as all other existing securities. Insurance companies can simply cancel out the risk
by issuing an equal number of both securities, and generate profits through their
intermediary function. Given relative investments in vaccine development and drug
production, the demand for the Arrow security should be greater than that for its
complement. International agencies in charge of promoting access to drug treatment
can then take the residual risk by issuing Arrow securities, and possibly charging
a premium in the form of a reduction in subsidies to developing countries. Our
welfare analysis also directly implies that security issuance is more efficient than
direct subsidies. As a whole, our construction implies that every party can fully cover
the risk of the appearance (or not) of a vaccine (see Figure 1).
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Figure 1: Issuance and demand for securities
In the next section, we develop a two-period model representing a typical HIV/AIDS
care decision setting for a developing country, in a general equilibrium framework en-
compassing all the above issues. This analysis aims to show that the demand for
Arrow securities is motivated by welfare considerations.
In our framework, the government allocates resources to enhance national con-
sumption, provision of a public good and production of ARV treatments for a given
level of endowments (which include a given level of international subsidies). There
is also a vaccine agency in charge of developing the vaccine as well as distributing
it to the government at no cost. This agency allocates its own endowment between
funding the vaccine distribution to the government if the vaccine R&D campaign
is successful, and refinancing a new R&D campaign otherwise. We assume that in
the second period a vaccine is available with exogenous positive probability; that is,
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we assume that current investment from the vaccine agency does not influence the
success probability.
Arrow securities and their complementaries are issued by a large number of risk-
averse investors having access to a complete financial market. Investors have standard
von Neumann-Morgenstern preferences, and we assume that there is zero-covariance
in return between the Arrow security and a large market portfolio. A straightforward
application of the beta-pricing formula to this setting implies that the equilibrium
price of one Arrow security paying off one unit of consumption good equals the prob-
ability of appearance of the vaccine (actuarial price). We then show that, if the level
of international subsidies decreases as a consequence of the availability of the vac-
cine, the optimal reaction of a government is to increase its security holdings. We
also show that the introduction of Arrow securities strictly improves expected social
welfare. Finally, holding of Arrow securities is shown to guarantee a higher level of
treatment investments and a higher level of provision of the public good.
The intuition behind our results is that, when faced with the risk of a drop in
contingent endowment, the need to smooth out losses from ARV production becomes
more and more pressing for a developing country. The Arrow security is the only
way to achieve this optimal smoothing. At a more abstract level, the reason for
this improvement is that our securities allow to switch from an uninsurable risk to
complete financial markets where every insurance needs are met.
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4 The model
We next develop a formal model that encompasses the previously described issues in
a General Equilibrium framework. We will put the emphasis on showing that Arrow
securities are demanded by governments in developing countries to foster social wel-
fare, provision of public goods and investments in drug treatments. All the technical
proofs in this section are given in the Appendix.
There are two periods (t = 0 and t = 1), and a given population of infected
patients in period 0. A benevolent government is in charge of treating the patients.
Every infected agent must receive medical treatment in period 1, or else dies during
this period. Potentially, there are two forms of medical treatment that guarantee
the survival of the infected patient. The first one is a pill of ARV drug, with the
assumption that technical knowledge exists in period 0 to start production in period
1.1 The alternative to this treatment is a therapeutic vaccine (or any other inno-
vation outdating existing treatments) available in period 1 with positive probability
described next.
4.1 The vaccine agency
The vaccine is developed in period 0 by a vaccine agency. In period 1, it becomes
common knowledge whether the development campaign started in period 0 is success-
1For instance, this pill can be a Fixed Dose Combination (FDC) currently produced by Indian
firms. Luchini et al. (2003) analyzes the current provision of ARV drugs in developing countries.
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ful. If the vaccine is available in period 1, the agency funds a distribution campaign
to treat the infected population. Otherwise, the agency seeks to finance a new R&D
campaign to start in period 1. To simplify the analysis, we assume that period 0
investments in R&D are already in place, and thus financial decisions do not affect
the success probability of the vaccine development. Thus, we assume that a vaccine
appears in period 1 with exogenous probability α > 0. The agency has an initial ex-
ogenous endowment wa0 > 0 of consumption good in period 0, which can be allocated
to hedge against period 1 events. The agency also receives an endowment wa1 > 0 of
consumption good in period 1 if the development campaign is successful to fund the
distribution to developed countries, and wa2 > 0 to fund another R& D campaign in
case of failure. We assume that wa2 > 0 is significantly smaller than w
a
1 > 0 so that
the agency must hedge against failure to successfully develop the vaccine. Let ρ > 0
(resp. σ > 0) denote the funds allocated in period 0 to the distribution campaign
(resp. to the new R&D campaign). From a bundle (ρ, σ), the vaccine agency receives
the utility
Ua(ρ, σ) = αΠ1(ρ) + (1− α)Π2(σ), (1)
where Πi (i = 1, 2) is a strictly increasing, strictly concave function and continuously
differentiable function. The functions Πi’ can be regarded as continuation functions
describing the objectives above; moreover, the budget constraints faced by the agency
to funds those campaigns will be described later after describing the financial tools
allowing to hedge against variations in subsidies as described above.
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4.2 The government
We now describe the government decision problem. The government can turns the
consumption good into ARV treatments and a public good, or can also consume
directly. The government thus faces a problem of optimal allocation of resources
between national consumption, treatment of the infected population and the provision
of a public good such as schools or roads.
The government receives an exogenous endowment w0 > 0 of consumption good
in period 0. This endowment is the only source of revenue, which can come from
capital in place, direct taxation and/or international subsidies. In period 1, the
government has an endowment of consumption good w1 > 0 if the vaccine is available,
and w2 > 0 otherwise. We assume that w1 is significantly smaller than w2 for the
reasons described in Section 2, giving incentives to the government to hedge against
this fluctuation in endowments in a way described later with the government budget
constraints. Let c0 denote the amount of consumption good consumed in period 0,
and let c1 (resp. c2) denote the amount of consumption good consumed in period 1
if the vaccine is available (resp. if not available).
The government is also in charge of producing a public good and ARV treatments.
Those are produced in period 0, and are distributed at no cost to the population in
period 1. For sake of simplicity, we assume that for any amount of consumption good
g ≥ 0, the government uses a one-to-one technology to produce a measure g of public
good.
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The government also uses a one-to-one technology to produce ARV treatments.
A measure T of ARV treatment has two components, one component g′ that can
be turned into public good if the vaccine appears, and a component d that is AIDS
specific and is lost if a vaccine appears. The component d will be called treatments.
To simplify the analysis, we assume that the component g′ is embedded into the
provision of public good g.
The public good and treatments produced are distributed to the population at no
cost (public good and treatments are not marketable). If the vaccine is available, it is
distributed to the population at no cost to the government by the agency. The utility
derived by the government from a sequence (c0, c1, c2, d, g) is given by the welfare
function
U(c0, c1, c2, d, g) = u(c0) + βα[u(c1) + v(g)] + β(1− α)[u(c2) + v(g) + Γ(d)], (2)
where β > 0 is an intertemporal discount factor, and where the functions u, v and Γ
are all strictly increasing, strictly concave, twice-continuously differentiable and sat-
isfy the Inada conditions. The function Γ measures the specific emphasis on treating
the infected population regardless of possible losses. The function u (resp. v) mea-
sures the utility derived from consumption good (resp. public good). The functions
Γ and v can depend on the level of infected population, political priorities or other
demand for health expenditures.
The separability of the objective function in (2) captures the idea that there is no
substitution effect across goods and across time, and it is not central to our analysis.
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Similar qualitative results obtain by assuming, instead of separability, supermodular-
ity of the objective function or a single crossing property on some parameters of the
economy (see Topkins (1998) for a mathematical introduction). The mathematical
difficulties raised by those weaker assumptions are beyond the scope of our analysis.
4.3 The financial tools
We also assume that the government and the agency trade securities to hedge against
the appearance (or not) of the vaccine. The need to the government for this hedging
opportunity arises from the loss of prior investment in treatments in the event of a
successful vaccine. In the same manner, the need to the vaccine agency is motivated
by losses incurred in restructuring the R&D in case of non-appearance.
We next describe the financial tools making those insurance opportunities possible.
Consider a financial asset available in period 0, paying off one unit of consumption
good next period if the vaccine is made available and 0 unit of consumption good
otherwise. We call this asset an Arrow security. This Arrow security works as an
security with maturity date being one period ahead and payment contingent on the
introduction of the vaccine. If the vaccine is not available in period 1, the Arrow
securities become worthless. Define the complementary security as above, with the
only difference that it pays off 1 unit of consumption if the vaccine does not appear
and 0 otherwise.
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4.4 International investors
Arrow securities and the complementary securities are traded (or issued) by interna-
tional investors represented by an arbitrary non-empty set I, which have access to a
large financial market assumed to be complete. In more details, any investor in this
outside market faces L ≥ 2 intrinsic events independent of the vaccine appearance,
each event l (l = 1, ..., L) receives probability γl > 0 all summing up to 1. We in-
corporate the new risk of a vaccine appearance as follows: every intrinsic event l is
separated into two events l1 and l2, where l1 corresponds to event l with vaccine ap-
pearance (thus occurring with probability γl ·α) and l2 is the event l without vaccine
appearance occurring with probability γl · (1− α).
When describing above the objective of the agency and the government, we have
implicitly assumed that those bodies consider the intrinsic events in this outside
market to be undistinguishable, and thus they do not seek to hedge against them.
The same results hold by removing this last assumption, we maintain it to simplify
the exposition. Investors trade J ≥ L securities, and every security j purchased in
period 0 yields in period 1 a dividend dlj ≥ 0 in consumption good if the intrinsic
event l occurs. Investors also trade Arrow securities and complementary securities.
We assume that this outside financial market is complete, and thus contains a risk-free
asset whose return is normalized to 1.
Every investor i receives an endowment in consumption good wi0 > 0 in period 0,
and contingent endowment wilj > 0 if the event lj (l = 1, ..., L and j = 1, 2) occurs in
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period 1.
Investors are risk-averse and take financial positions so as to maximize the stan-
dard utility function
V (c0, c˜) = f(c0) + E [f(c)] , (3)
where c˜ is the vector of consumption good in period 1, E[.] is the expectation operator
associated with the economic uncertainty in the outside market, and f is a strictly
increasing, strictly concave and continuously differentiable function. The budget con-
straints faced by the international investors is described in the next section.
4.5 Budget constraints and equilibrium definition
We now describe the problem faced by the government, the vaccine agency and the
international investors. Let za denote the amount of Arrow securities purchased by
the government, and let pa be the price of one security. The budget constraint in
period 0 faced by the government is given by
c0 + g + d+ paza ≤ w0, and c0, g, d ≥ 0. (4)
In the above, we have not restricted security holdings to being positive, thus al-
lowing for short sales. We will later give a sufficient condition, based on contingent
endowments, ensuring that the government holds a strictly positive quantity of secu-
rities. It is also easy to see that short-selling also allows not to consider holdings of
the complementary security in (4).
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In period 1, contingent on the availability of the vaccine and with a holding za of
Arrow securities, the budget constraints are given by
c1 ≤ w1 + za, c1 ≥ 0 and c2 ≤ w2, c2 ≥ 0. (5)
We next describe the budget constraint of the vaccine agency. Let zc denote the
amount of complementary securities purchased by the government, and let pc be the
price of one security. The budget constraint in period 0 of the vaccine agency is given
by
ρ+ σ + pczc ≤ wa0 , (6)
and in period 1 the budget constraints are given by
ρ ≤ wa1 , ρ ≥ 0 and σ ≤ wa2 + zc, σ ≥ 0. (7)
Here again, the possibility of short-selling the complementary security allows not
to consider holdings of Arrow security in (6). Moreover, the drop in contingent endow-
ments as described in Section 4.1 justifies the holdings of complementary securities
only.
Finally, we define the budget constraints of the international investors. Let pj be
the period 0 purchasing price of security j on the outside market and let θj be the
holding of this security j. The budget constraint in period 0 of investor i ∈ I is
c0 + pcθc + paθa +
∑
j
pjθj ≤ wi0, (8)
and in period 1 they are given for every intrinsic event l by
cl1 ≤ wil1 + θc +
∑
j
dl1j θj, and cl2 ≤ wil2 + θa +
∑
j
dl2j θj. (9)
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Let θi be the vector of holdings of securities for investor i, and let ci = (ci0, c11 , ..., cL2)
be her vector of contingent consumption. Let also pM = (pj)j=1,...,J denote the vector
of asset prices on the outside market.
We can now define an equilibrium for this economy.
Definition 1 A financial equilibrium is a sequence (c0, c1, c2, d, g, za, ρ, σ, zc), a se-
quence (ci, θ
i
)i∈I and asset prices (pa, pc, pM) such that
1. taking as given pa, the sequence (c0, c1, c2, d, g, za) is a solution to the program
of maximizing (2) subject to (4) and (5);
2. taking as given pc, the sequence (ρ, σ, zc) maximizes (1) subject to (6) and (7);
3. taking as given (pa, pc, pM), for every i the sequence (c
i, θ
i
) maximizes (3) subject
to (8) and (9);
4. all markets clear.
Thus at the equilibrium, the government seeks to maximize its utility function
taking the asset price of the Arrow security as given, so does the vaccine agency
with the price of the complementary security, and risk-averse investors maximize their
objective functions taking as given all the asset prices. As usual in general equilibrium
models, the asset price is determined by market clearing conditions. One can also
notice that the equilibrium price of the Arrow security must be strictly positive, since
otherwise by (4) and (5), and together with the fact that the functions u and v are
strictly increasing, the government would have an infinite demand for this asset. The
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same holds for the complementary security, since otherwise the vaccine agency would
have an infinite demand by the same reasoning.
We next impose a condition on the correlation between the risk of a vaccine
appearance and a market portfolio.
Assumption 2 There is a market portfolio m lying on the mean-variance frontier,
such that there is 0-covariance in return between m and the Arrow security.
In practice, any standard market index can be considered to meet the requirement in
Assumption 2. The above assumption is natural, since it seems unlikely that a non-
patented product has a significant impact on a large portfolio such as the S&P 500.
This assumption allows to pin down the equilibrium price of the security, following
standard arguments of the CAPM (see Leroy and Werner (2001), Chapter 17-19).
Following again a CAPM type of argument, Assumption 2 also implies that Arrow
securities can be used as any other tool to diversify any risk faced by international in-
vestors. The next result is a straightforward consequence of the beta-pricing formula,
when applied to our setting.
Proposition 3 In equilibrium, we have that p¯a = α.
Proposition 3 states that the equilibrium price of the Arrow security is exactly
the probability of appearance of the vaccine. Such price corresponds to the actuarial
price (or fair price) that any investor would expect in a real market for this asset.
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4.6 Welfare analysis
We now study some welfare properties of a financial equilibrium. We first carry out
some comparative statics on the fundamentals of the economy. In particular, we are
interested in analyzing the effect of a drop in international subsidies on the holding
of Arrow securities if a vaccine becomes available. Such a decrease in international
subsidies can be justified by a reallocation of resources at an international level to
the production and distribution of the vaccine.
Proposition 4 In equilibrium, if w1 decreases and all else remains equal, then the
equilibrium holding of Arrow securities increases.
Proposition 4 states that a drop in international subsidies, as a consequence of
the appearance of a vaccine, leads the government to increase its security holdings.
The intuition is that, when facing the risk of a drop in contingent endowment, the
need to smooth out loss of drug production becomes more and more stringent to
the government. The Arrow security is the only way in our economy to achieve this
optimal smoothing.
At this point, the government still has the opportunity to short-sell the security,
depending on the level of contingent endowments. The possibility of short-sales shows
an additional property of the Arrow security: the government can also use the asset
to smooth out contingent consumption of various goods even if the vaccine does not
appear. If contingent endowment in this last event is anticipated to be high, the
government can thus short-sell the security to increase contingent consumption in
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the event of non-appearance. The optimal level of security holdings in Proposition 4,
which includes the possibility of short-sales, depends on various fundamentals of the
economy such as government preferences and contingent endowments.
Our next result gives a sufficient condition on contingent endowments ensuring no
short-sale of Arrow securities in equilibrium.
Proposition 5 There exists e > 0 such that, for every w1 ≤ e, we have that za > 0
in equilibrium.
Propositions 4 and 5 together show that, if a significant drop in contingent en-
dowment occurs in the event of a successful vaccine, the government finds it optimal
to hold a positive amount of Arrow securities. Moreover, by Proposition 3, the equi-
librium price of the Arrow security is not affected by a decrease in w2. Thus, a moral
hazard based on manipulation of international subsidies is ruled out in our setting.
Hedging decisions are thus solely driven by consumption smoothing and welfare issues.
We next study the influence of the Arrow security on equilibrium supply of treat-
ments and the public good. We first define a notion of equilibrium without financial
assets. We call a sequence (c˜0, c˜1, c˜2, d˜, g˜) a production equilibrium if (c˜0, c˜1, c˜2, d˜, g˜)
is solution to the program of maximizing (2) subject to (4)-(??) with the additional
constraint that za = 0. Thus, a production equilibrium is simply an optimal alloca-
tion of resources towards the production of various goods without access to financial
tools. Our next result compares some properties of the financial and the production
equilibria.
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Proposition 6 Assume that w1 ≤ e, where e is given by Proposition 5. The equilib-
rium supply of the public good and treatments is strictly higher in a financial equilib-
rium than in a production equilibrium.
Proposition 6 compares equilibrium supplies of various goods, when contingent
endowment is significantly low in the event of a successful vaccine. This case is the
most relevant one, as explained in Section 2. Proposition 6 states that the introduc-
tion of the Arrow security increases drug production and public good delivery to the
population. Thus, availability of the security allows the government to increase the
number of treated patients without sacrificing efficiency. Since this increase would
be impossible without the security, we have thus established the importance of our
financial tool.
5 Conclusion
Our work shows that public investments in innovative treatments for current diseases
is an economic disincentive to existing treatment production in developing coun-
tries. That is, developing countries are expected to rationally under-invest in existing
treatment production when they cannot hedge against the introduction of innovative
treatment technologies, the level of under-investment depending on anticipations of
future medical innovations. This is not only the case for AIDS, as considered here,
but also for major epidemics such as tuberculosis, malaria, sleeping sickness, Chagas
disease and Dengue fever. The availability of financial securities allowing develop-
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ing governments to hedge against future innovations is shown here to foster existing
treatment production, social welfare as well as innovative treatment technologies.
Thus, we argue that an international body’s decision to invest in R&D of not-yet
patented treatments should be accompanied by the creation of financial securities such
as the Arrow security and its complementary security introduced here. One of the
limitations of our proposition is that international bodies themselves might be subject
to moral hazard, since they could provide false information about future availability of
technologies in order to manipulate governments’ current investment decisions and the
prices of the derivatives. Consequently, full transparency of information about R&D
is necessary to eliminate such a moral hazard and to allow for accurate estimation of
the risk effectively taken by insurance companies.
The health sector is however well designed to guarantee such transparency. For
instance, the Summit of Health Ministers held in Mexico in November 2004 endorsed
a WHO proposal to establish an international platform to register all ongoing clinical
trials sponsored either by the public or private sector. Biomedical journals are also
issuing guidelines that would ultimately forbid publication of trial results that would
not have been previously approved by this platform.
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A Appendix
We now prove the technical results stated earlier.
A.1 Proof of Proposition 3
Given our setting, we are typically in the situation of the CAPM. Moreover, since
markets are complete, the equilibrium price must equal the marginal rate of substi-
tution of any agent in the economy.
Consider now any international investor. The first-order conditions to her opti-
mization program allows to pin down the unique pricing kernel of the economy as a
function of her preferences. Following now exactly the same lines as Theorem 19.2.1
in Leroy and Werner (2001), by rearranging the terms of the pricing kernel and using
the fact that the market return lies on the mean-variance frontier, we obtain that
E(ra) = r¯ + βa (E(rm)− r¯) , (10)
where ra (resp. rm) is the return of the Arrow security (resp. market portfolio m),
βa =
cov(ra,rm)
var(rm)
is the usual “beta” for the Arrow security in the beta-pricing formula,
and r¯ is the risk-free return already normalized to be 1. By Assumption 2, we have
that βa = 0 and (10) rewrites as
E(a) = r¯ = 1. (11)
Since E(a) = α
p¯a
, we thus have that p¯a = α and the proof is complete.
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A.2 Proof of Propositions 4
The proof of Proposition 4 starts by analyzing the program faced by the government
in equilibrium.
Since the utility functions are strictly increasing, the budget constraints in (4) and
(5) must be binding. This implies that the program faced by the government can be
rewritten as
Maxd,g≥0,za u(w0−paza−d−g)+βαu(w1+za)+β(1−α) (u(w2) + Γ(d))+βv(g). (12)
We can now notice that, by the Inada conditions, the solution variables (d, g)
to the above program must be strictly positive. Moreover, since we have placed no
restriction on the security holding, the Lagrangian to the above programm is
L = u(w0 − paza − d− g) + βαu(w1 + za) + β(1− α) ((u(w2) + Γ(d)) + βv(g). (13)
Taking the first order conditions, and using the price relation given in Proposition
3, we obtain the following equilibrium relations:
u′(w0 − paza − d− g) = βu′(w1 + za), (14)
u′(w0 − paza − d− g) = βv′(g), and (15)
u′(w0 − paza − d− g) = β(1− α)Γ′(g). (16)
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Rearranging the above equations, we obtain that
u′(w1 + za) = βv′(g), and (17)
u′(w1 + za) = β(1− α)Γ′(d), . (18)
To prove our result, we now proceed by way of contradiction. Assume that two
endowments exist w11 and w
2
1 such that w
1
1 > w
2
1 and z
1
a ≥ z2a. By (14), we must have
that
w0 − paz1a − d
1 − g1 > w0 − paz2a − d
2 − g2. (19)
Rearranging and using the fact that z1a ≥ z2a, we get that
d
2
+ g2 > d
1
+ g1. (20)
Moreover, by equations (17) and (18), we also have that d
1
> d
2
and g1 > g2.
This contradicts equation (20), and the proof of Proposition 4 is now complete.
A.3 Proof of Proposition 5
To prove our result, we now proceed by way of contradiction. Assume that a sequence
(wn1 )n≥0 and corresponding solutions (z
n
a)n≥0 exist, such that w
n
2 → 0 and zna ≤ 0.
By Proposition 4, the sequence (zna)n is increasing and thus bounded from below.
It follows that (zna)n converges to some z˜a ≤ 0. By equation (14), the expression
wn0 − pazna − d
n − gn converges to 0.
Moreover, it must be true that gn and d
n
converge to 0 for (17) and (18) to hold.
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Thus, it follows from the above that paz
n
a converges to w0. Since w0 is strictly
positive, and since the price pa depends only on α, we have established that z˜a > 0,
which is a contradiction. The proof is now complete.
A.4 Proof of Proposition 6
In a financial equilibrium, it follows from (17) and (18) that the equilibrium quantities
of public good and drugs must satisfy the following relations
u′(w1 + za) = βv′(g) and (21)
u′(w1 + za) = (1− α)βΓ′(d), (22)
where za is the optimal holding of Arrow securities. Since w1 ≤ e, it follows from
Proposition 4 that za > 0.
Without tradable securities, it must be true that za = 0 is the solution to the
program faced by the government, and thus we must have that
u′(w1) = βv′(g˜) and (23)
u′(w1) = β(1− α)Γ′(d˜), (24)
where g˜ and d˜ are optimal variables in the production equilibrium. Since u′, v′ and
Γ′ are monotonic functions, and since za > 0, it follows that g > d˜ and d > d˜. The
proof is now complete.
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